CD8A and B-cell chronic lymphocytic leukemia: In summary, although there is evidence suggesting that pre-clinical as well as clinical PI3Kδ inhibition in CLL diminishes CD8+ T-cell function (Figure 3), further studies investigating patient samples are needed to fully elucidate the effects of inhibited PI3Kδ signaling on CD8+ T-cells in CLL.